Mylan (MYL) announced the U.S. launch of Fenofibrate Tablets USP, 40 mg and 120 mg, a generic version of Santarus's Fenoglide. The product is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, and apolipoprotein B to increase high-density lipoprotein in adult patients with primary hypercholesterolemia or mixed dyslipidemia. According to IMS Health, total U.S. sales were ~$28.6M for the year ending April 30. Currently, Mylan has 246 ANDAs pending FDA approval representing $107.4B in annual brand sales.